BT
CTNM

Banque Transatlantique’s Contineum Therapeutics CTNM Stock Holding History

Banque Transatlantique’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.95K Hold
220
– – ﹤0.01% 406
2025
Q4 		$2.51K Buy
+220
New +$2.51K ﹤0.01% 239

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Banque Transatlantique's CTNM Position: Q1 2026 in Review

Banque Transatlantique held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 220 shares worth $2.95K. The position accounts for ﹤0.01% of the portfolio, ranked #406.

Banque Transatlantique first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Banque Transatlantique held 220 shares of Contineum Therapeutics worth $2.95K as of Q1 2026.
  • Banque Transatlantique left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up ﹤0.01% of Banque Transatlantique's portfolio in Q1 2026, its #406 holding.
  • Banque Transatlantique first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Banque Transatlantique's 13F filing for Q1 2026, filed 13 May 2026.